Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMQDKYI)

Drug Name

3,4'-(1H-1,2,4-triazole-3,5-diyl)dipyridine Drug Info

Synonyms

CHEMBL1077387; 36770-51-1; 1H-3-(3-pyridyl)-5-(4-pyridyl)-1,2,4-triazole; AC1LJ7ET; SCHEMBL11592234; MolPort-002-889-160; BDBM50311281; STL442012; CCG-42398; ZINC18164784; AKOS002669464; AKOS005228430; AKOS002732698; MCULE-6941572691; FT-0749446; 3,4''-(1H-1,2,4-triazole-3,5-diyl)dipyridine; SR-01000632401-1; 3-(5-pyridin-4-yl-1H-1,2,4-triazol-3-yl)pyridine; 3-(3-Pyridyl)-5-(4-pyridyl)-1H-1,2,4-triazole

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 918281
CAS Number: CAS 36770-51-1
TTD Drug ID: DMQDKYI

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting Xanthine dehydrogenase/oxidase (XDH)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Allopurinol	DMLPAOB	Gout	FA25	Approved	[2]
Febuxostat	DMDEXQ0	Hyperuricaemia	5C55.Y	Approved	[3]
Fosdenopterin	DMR0TYK	Molybdenum cofactor deficiency	5B5K.A	Approved	[4]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[5]
Oxypurinol	DMURH4X	Heart failure	BD10-BD13	Phase 2/3	[6]
BAICALEIN	DM4C7E6	Influenza virus infection	1E30-1E32	Phase 2	[7]
Topiroxostat	DMA04DE	Gout	FA25	Phase 2	[8]
TMX-049	DME8PFQ	Diabetic nephropathy	GB61.Z	Phase 2	[9]
LC-350189	DMHT3CB	Gout	FA25	Phase 1	[10]
Azaindole derivative 5	DMD2BL3	N. A.	N. A.	Patented	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Xanthine dehydrogenase/oxidase (XDH)	TT7RJY8	XDH_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Discovery of 3-(2-cyano-4-pyridyl)-5-(4-pyridyl)-1,2,4-triazole, FYX-051 - a xanthine oxidoreductase inhibitor for the treatment of hyperuricemia [... Bioorg Med Chem Lett. 2009 Nov 1;19(21):6225-9.
2	Allopurinol: xanthine oxidase inhibitor. Tex Med. 1966 Jan;62(1):100-1.
3	Clinical pipeline report, company report or official report of Takeda (2009).
4	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
5	Inhibition studies of bovine xanthine oxidase by luteolin, silibinin, quercetin, and curcumin. J Nat Prod. 2009 Apr;72(4):725-31.
6	Oxypurinol as an inhibitor of xanthine oxidase-catalyzed production of superoxide radical. Biochem Pharmacol. 1988 Jan 15;37(2):349-52.
7	Inhibition of cow's milk xanthine oxidase by flavonoids. J Nat Prod. 1988 Mar-Apr;51(2):345-8.
8	QT/QTc study conducted in Japanese adult healthy subjects: a novel xanthine oxidase inhibitor topiroxostat was not associated with QT prolongation. J Clin Pharmacol. 2014 Apr;54(4):446-52.
9	Clinical pipeline report, company report or official report of Teijin Pharma.
10	Pharmacokinetics, pharmacodynamics, and tolerability of LC350189, a novel xanthine oxidase inhibitor, in healthy subjects. Drug Des Devel Ther. 2015 Aug 31;9:5033-49.
11	An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345.